Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

S&P 500: Outlook Constructive but Concerns Remain

Key Points:<ul>
<li>The Staples Sector is leadership and many names are staging price and RS reversals.</li>
<li>REIT’s are breaking above bases and are showing RS leadership.</li>
<li>Paper &amp; Forest products are strengthening and many are reversing price and RS downtrend or breaking above bases.</li>
<li>Large-Cap Pharma stocks are showing leadership. Many have broken topside of multi-year consolidations or have reversed multi-year price and RS downtrends.</li>
</ul><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/059/921/original/Untitled.png?1533586859" class="editor-image img-responsive" data-smartkarma-image-id="59921"></figure>

Key Points:
The Staples Sector is leadership and many names are staging price and RS reversals.
REIT’s are breaking above bases and are showing RS leadership.
Paper &amp; Forest products are strengthening and many are reversing price and RS downtrend or breaking above bases.
Large-Cap Pharma stocks are showing leadership. Many have broken topside of multi-year consolidations or have reversed multi-year price and RS downtrends.


Today's key points:<ul>
<li>Property &amp; Casualty Insurance names are staging price and RS reversal and/or breakouts.</li>
<li>Airlines are staging price and SR reversals to the upside and/or are breaking out.</li>
<li>Railroad related names are breaking out.</li>
<li>We have been bearish on the Semiconductor and Suppliers industry since February; however we are seeing some near term reversals at support levels.</li>
</ul>Highlighted charts: SUP, CMG, LOCO, MCS, EXPE, AMZN, WBA, K, NR, NOV, SLCA, BHGE, OIS, HLX, JPM, WFC, KEY, AXP, AFL, TMK, HSIC, ZBH, OMCL, ANTM, LLY, PFE, AGN, B, WM, ESND, ECHO, and SKYW.

Today's key points:
Property &amp; Casualty Insurance names are staging price and RS reversal and/or breakouts.
Airlines are staging price and SR reversals to the upside and/or are breaking out.
Railroad related names are breaking out.
We have been bearish on the Semiconductor and Suppliers industry since February; however we are seeing some near term reversals at support levels.
Highlighted charts: SUP, CMG, LOCO, MCS, EXPE, AMZN, WBA, K, NR, NOV, SLCA, BHGE, OIS, HLX, JPM, WFC, KEY, AXP, AFL, TMK, HSIC, ZBH, OMCL, ANTM, LLY, PFE, AGN, B, WM, ESND, ECHO, and SKYW.

U.S. Vital Signs - Actionable Charts of the Day

Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Equity Bottom-Up

Background - <a href="https://www.smartkarma.com/entities/21001" target="_blank" data-smartkarma-citation="entities:21001:1">Eisai Co Ltd (4523 JP)</a> on December 21, 2017, announced that 12 months data on BAN2401 did not meet its primary endpoint (<a href="https://www.eisai.com/news/news201773.html" target="_blank">link</a>), leaving little hope for 18 months data.As a result, earlier on July 6, 2018, when Eisai announced positive efficacy at the highest treatment dose of 10mg/kg (monthly / bi-weekly) from the same study, based on 18 months data, we advised caution (<a href="https://www.smartkarma.com/insights/ban2401demonstrates-statistically-significant-clinical-data-for-18-months-study" target="_blank" data-smartkarma-citation="insights:21938">BAN2401Demonstrates Statistically Significant Clinical Data for 18 Months Study</a>) on the positive stock reaction…

Background - Eisai Co Ltd (4523 JP) on December 21, 2017, announced that 12 months data on BAN2401 did not meet its primary endpoint (link), leaving little hope for 18 months data.As a result, earlier on July 6, 2018, when Eisai announced positive efficacy at the highest treatment dose of 10mg/kg (monthly / bi-weekly) from the same study, based on 18 months data, we advised caution (BAN2401Demonstrates Statistically Significant Clinical Data for 18 Months Study) on the positive stock reaction…

BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

In <a href="https://www.smartkarma.com/insights/takeda-shire-i-on-drug-deals-and-deckchairs" target="_blank" data-smartkarma-citation="insights:20087">Takeda/Shire I : On Drug Deals and Deckchairs</a> I discussed the Drug Deal (the terms to the deal) and the Deckchairs - the significant reshuffling of shareholder ownership required between now and a month or two after the deal is consummated. 
Since the deal was announced, the spread to terms has remained stubbornly wide as investors in <a href="https://www.smartkarma.com/entities/22142" target="_blank" data-smartkarma-citation="entities:22142:1">Shire PLC (SHP LN)</a> and foreign investors in <a href="https://www.smartkarma.com/entities/11747" target="_blank" data-smartkarma-citation="entities:11747:1">Takeda Pharmaceutical Co Ltd (4502 JP)</a> have worried about a shareholder proposal from Takeda dissidents to be dealt…

In Takeda/Shire I : On Drug Deals and Deckchairs I discussed the Drug Deal (the terms to the deal) and the Deckchairs - the significant reshuffling of shareholder ownership required between now and a month or two after the deal is consummated. 
Since the deal was announced, the spread to terms has remained stubbornly wide as investors in Shire PLC (SHP LN) and foreign investors in Takeda Pharmaceutical Co Ltd (4502 JP) have worried about a shareholder proposal from Takeda dissidents to be dealt…

Takeda/Shire II:  Drugs, Divvies, and AGM Votes

United States

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pfizer (PFE UN)

S&P 500: Outlook Constructive but Concerns Remain

As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...

Vermilion Research

U.S. Vital Signs: Actionable Stocks

Key Points: The Staples Sector is leadership and many names are staging price and RS reversals. REIT’s are breaking above bases and are showing RS...

Vermilion Research

U.S. Vital Signs - Actionable Charts of the Day

Today's key points: Property & Casualty Insurance names are staging price and RS reversal and/or breakouts. Airlines are staging price and SR...

Vermilion Research

BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns

Background - Eisai Co Ltd (4523 JP) on December 21, 2017, announced that 12 months data on BAN2401 did not meet its primary endpoint (link),...

Dion Stéfan Büchner M.D., FCAP

Takeda/Shire II: Drugs, Divvies, and AGM Votes

In Takeda/Shire I : On Drug Deals and Deckchairs I discussed the Drug Deal (the terms to the deal) and the Deckchairs - the significant reshuffling...

Travis Lundy

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)